Learn more about approved factor VIII replacement therapy ALTUVIIIO® [Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein-ehtl].

Explore how ALTUVIIIO® [Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein-ehtl] works in the body. See detailed Safety Information.

This is information from a study of 13 previously treated adults with with severe hemophilia A that had the goal of comparing how long ALTUVIIIO, Adynovate ® [Antihemophilic Factor (Recombinant), PEGylated], and Advate ® [Antihemophilic Factor (Recombinant)] stayed in the body after 1 dose. Half-life was 43 hours for ALTUVIIIO, 15 …

This is information from a study of 13 previously treated adults with severe hemophilia A, that had the goal of comparing how long ALTUVIIIO, Adynovate ® [Antihemophilic Factor (Recombinant), PEGylated], and Advate ® [Antihemophilic Factor (Recombinant)] stayed in the body after 1 dose. Half-life was 43 hours for ALTUVIIIO, 15 hours for Adynovate, and 11 hours for Advate.

ALTUVIIIO ® [antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein-ehtl] is an injectable medicine that is used to control and reduce the number of bleeding episodes in people with hemophilia A (congenital Factor VIII deficiency). Your healthcare provider may give you ALTUVIIIO when you have surgery.

Hemophilia A is an inherited disorder passed down from male or female parents that causes the clotting protein Factor VIII to be missing or not work properly. This is also referred to as Factor VIII deficiency.

Explore financial support options and resources for eligible patients on ALTUVIIIO® [Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein-ehtl]

INDICATION ALTUVIIIO® [antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein-ehtl] is an injectable medicine that is used to control and reduce the number of bleeding episodes in people

Download tools and resources for your ALTUVIIIO journey, including a quick guide, infusion overview, patient services enrollment form, and doctor discussion guide.

Half-life is the length of time that it takes for only half of the drug to remain active in a patient’s body. The half-life of factor VIII varies among patients and can be influenced by age, presence of inhibitors, and the specific factor VIII products that are used in the treatment.